Literature DB >> 10717157

Hypoxia and Radiation Response in Human Tumors.

.   

Abstract

This study demonstrates by an updated analysis of an ongoing prospective study that tumor oxygenation, as measured with a validated standardized polarographic needle electrode method before treatment, powerfully predicts the prognosis of patients receiving radiotherapy for intermediate and advanced stage cancer of the uterine cervix. First evidence for a host component in tumor oxygenation based on a significant correlation between median pO(2) values determined in normal subcutaneous fatty tissue and in cervical cancer is also presented. Further investigations are necessary to clarify whether tumor hypoxia is just a marker of intrinsic tumor aggressiveness or whether the negative impact of tumor hypoxia on survival is related to radiobiological mechanisms caused by hypoxia per se, which may include (1) the reduced oxygen enhancement effect, (2) increased radioresistance due to expression of genes for cell cycle delay and stress proteins, and/or (3) accelerated tumor progression to more radioresistant and metastatic variants by increased genetic heterogeneity.

Entities:  

Year:  1996        PMID: 10717157     DOI: 10.1053/SRAO0060003

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  58 in total

Review 1.  Applications of magnetic resonance in model systems: cancer therapeutics.

Authors:  J L Evelhoch; R J Gillies; G S Karczmar; J A Koutcher; R J Maxwell; O Nalcioglu; N Raghunand; S M Ronen; B D Ross; H M Swartz
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1.

Authors:  Isabel M Pires; Zuzana Bencokova; Chris McGurk; Ester M Hammond
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

3.  Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy.

Authors:  Arnaud Hocquelet; Thibaut Auriac; Cynthia Perier; Clarisse Dromain; Marie Meyer; Jean-Baptiste Pinaquy; Alban Denys; Hervé Trillaud; Baudouin Denis De Senneville; Véronique Vendrely
Journal:  Eur Radiol       Date:  2018-02-05       Impact factor: 5.315

4.  Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer.

Authors:  Ming-Huang Chen; Peter Mu-Hsin Chang; Po-Min Chen; Cheng-Hwai Tzeng; Pen-Yuan Chu; Shyue-Yih Chang; Muh-Hwa Yang
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-24       Impact factor: 4.553

Review 5.  Kinetic modeling in PET imaging of hypoxia.

Authors:  Fan Li; Jesper T Joergensen; Anders E Hansen; Andreas Kjaer
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

6.  Lysyl oxidase mediates hypoxia-induced radioresistance in non-small cell lung cancer A549 cells.

Authors:  Chongwen Gong; Runxia Gu; Honglin Jin; Yao Sun; Zhenyu Li; Jing Chen; Gang Wu
Journal:  Exp Biol Med (Maywood)       Date:  2015-10-28

Review 7.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

Review 8.  Measurements in vivo of parameters pertinent to ROS/RNS using EPR spectroscopy.

Authors:  Nadeem Khan; Harold Swartz
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

9.  The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone.

Authors:  Jin-Oh Kang; Seong-Eon Hong
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

10.  Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer.

Authors:  Nina A Mayr; William T C Yuh; David Jajoura; Jian Z Wang; Simon S Lo; Joseph F Montebello; Kyle Porter; Dongqing Zhang; D Scott McMeekin; John M Buatti
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.